Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:130196rdf:typepubmed:Citationlld:pubmed
pubmed-article:130196lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C2349001lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C0441833lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C0681850lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C1706203lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C2697811lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C0018595lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C0205307lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C1550501lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C1704711lld:lifeskim
pubmed-article:130196lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:130196pubmed:issue3 Suppllld:pubmed
pubmed-article:130196pubmed:dateCreated1976-6-2lld:pubmed
pubmed-article:130196pubmed:abstractTextAuthors have studied 758 sera from normal subjects in Marseille area. The genotype frequencie Hp 1 is 0,39, similar that of France in general. The phenotype repartition is 16% for Hp 1-1, 45% for Hp 2-1 and 39% for Hp 2-2. People with carcinoma have shown a increase of the frequencie of the phenotype Hp 2-2 and a decrease of the frequencie of genotype Hp 1, mostly in lung carcinoma (Hp 1 = 0,29) and in carcinoma of digestive track (Hp 1 = 0,19). However, a control group, which is constituted by people hospitalized in the Anti-Cancerous Center, has a Hp 1 frequencie of 0,29 a well as lung carcinoma, no explication was found.lld:pubmed
pubmed-article:130196pubmed:languagefrelld:pubmed
pubmed-article:130196pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:130196pubmed:citationSubsetIMlld:pubmed
pubmed-article:130196pubmed:statusMEDLINElld:pubmed
pubmed-article:130196pubmed:issn0037-9026lld:pubmed
pubmed-article:130196pubmed:authorpubmed-author:PoirierRRlld:pubmed
pubmed-article:130196pubmed:authorpubmed-author:KleisbauerJ...lld:pubmed
pubmed-article:130196pubmed:authorpubmed-author:ArnouxAAlld:pubmed
pubmed-article:130196pubmed:authorpubmed-author:LavalPPlld:pubmed
pubmed-article:130196pubmed:authorpubmed-author:ArtinianHHlld:pubmed
pubmed-article:130196pubmed:issnTypePrintlld:pubmed
pubmed-article:130196pubmed:volume169lld:pubmed
pubmed-article:130196pubmed:ownerNLMlld:pubmed
pubmed-article:130196pubmed:authorsCompleteYlld:pubmed
pubmed-article:130196pubmed:pagination811-4lld:pubmed
pubmed-article:130196pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:130196pubmed:meshHeadingpubmed-meshheading:130196-H...lld:pubmed
pubmed-article:130196pubmed:meshHeadingpubmed-meshheading:130196-N...lld:pubmed
pubmed-article:130196pubmed:meshHeadingpubmed-meshheading:130196-F...lld:pubmed
pubmed-article:130196pubmed:meshHeadingpubmed-meshheading:130196-P...lld:pubmed
pubmed-article:130196pubmed:meshHeadingpubmed-meshheading:130196-G...lld:pubmed
pubmed-article:130196pubmed:meshHeadingpubmed-meshheading:130196-G...lld:pubmed
pubmed-article:130196pubmed:year1975lld:pubmed
pubmed-article:130196pubmed:articleTitle[Study of the distribution of haptoglobin groups in Marseilles, in normal and in cancer subjects].lld:pubmed
pubmed-article:130196pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:130196pubmed:publicationTypeEnglish Abstractlld:pubmed